MacroGenics Q1 net loss $52.2M; interim TAMARACK data shows vobra duo activity in mCRPC

MACROGENICS INC

2024-Q1 EPS reported -$0.84 revenue$9,104,000

Q1 net loss $52.2M ($0.84/share) vs $38.0M loss in Q1 2023; total revenue $9.1M, down from $24.5M.
Cash, equivalents and marketable securities $184.2M as of March 31, 2024; cash runway expected into 2026.
Interim TAMARACK data: vobra duo 2.0 mg/kg q4W showed confirmed PSA≥50% reduction in 36/82 (43.9%) and ORR of 17.8%.
Five fatal AEs reported in TAMARACK; two pneumonitis deaths in 2.7 mg/kg cohort; Phase 3 planning initiated for 2025.
Company plans to expand TAMARACK to NSCLC, SCLC, melanoma and other indications in mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MACROGENICS INC reported financial results for quarter ended March 31, 2024.

Period: quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2024.

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

MACROGENICS INC filing history →

Source: SEC EDGAR

accession 0001125345-24-000091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.